Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

CVS Caremark Corporation (CVS - Analyst Report), one of the largest domestic integrated pharmacy services providers, recently updated its fiscal 2013 outlook and highlighted its growth framework, while reiterating its earlier guidance for the current year.

2013 Outlook

For fiscal 2013, the company expects earnings per share (EPS) of $3.59−$3.73 with adjusted EPS of $3.84−$3.98, representing annualized growth of 13%−17%. The current Zacks Consensus Estimate of $3.78 falls below the adjusted EPS guided range. The company also expects free cash flow to remain at an encouraging level of $4.8 billion– $5.1 billion with cash from operations of $6.4 billion−$6.6 billion.

CVS noted that the fiscal 2013 guidance excludes the anticipated benefit from the company's recent debt tender and refinancing, which is expected to result in an annual EPS accretion of approximately 2 cents due to the reduction of the interest expense. 

Further, CVS continued with its plan to deploy capital to boost shareholder confidence via dividends and share repurchases. The company expects to buy back shares worth $4 billion in fiscal 2013.  Additionally, its board of directors has approved a 38% increase in quarterly dividend to 22.5 cents per share, payable February 4, 2013. This hike will bring the payout ratio to 25%, the low end of its targeted range of 25%–30%, which will likely be achieved in another three years.

Reiterates 2012 Outlook

Anticipating a benefit from the company’s accelerated share repurchase program (announced in September 2012) and its expectation of retaining at least 60% of the prescriptions gained from the Walgreen Inc. (WAG - Analyst Report) and Express Scripts Holding Co. (ESRX - Analyst Report) impasse, CVS expects adjusted EPS in fiscal 2012 to remain in the range of $3.38−$3.41. The current Zacks Consensus Estimate of $3.37 falls below the guidance range.

The company also reiterated its 2012 free cash flow and cash flow from operations guidance of $4.6–$4.9 billion and $6.2–$6.4 billion, respectively. The fiscal 2012 guidance includes the completion of the accelerated share repurchase agreement of $1.2 billion.

Obamacare: A Big Boost

While discussing the long-term growth trajectory, CVS expected the implementation of the Affordable Care Act (ACA) or Obamacare to play in favor of the company by providing the much needed impetus to its business. CVS is upbeat regarding the fact that under the ACA, beginning 2014, there will be an additional 30 million people to join in the list of insured people. The company believes that with this massive increase in the insured aging population, there will be a huge demand for specialty drugs, which could present a big opportunity for companies like CVS.

We are impressed with the company’s fiscal 2013 guidance, which remained above our expectation. We are also confident about CVS’ long-term potential, based on its retail execution, deployment potential and the strong generics cycle. Moreover, we believe that the healthcare reform will open up new opportunities for the company. Currently, CVS retains a Zacks #3 Rank (short-term Hold). Over the long term, we have a Neutral recommendation on the stock.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%